david farcas | Director, Chile
Yelcho

Our History of Innovation and Partnership We are committed to delivering high-impact, innovative solutions to the animal health sector. Our background with Centrovet demonstrates our capabilities and success. • Market Leadership: As owners of Centrovet until its sale to Virbac in 2021, we held a 45% market share of salmon vaccines and a 50% market share of pharmaceuticals for salmonids. With 440 employees and a large R&D team (65 professionals), we were a leader in the industry. • Proven Impact: We successfully launched the first vaccine against ISA during the 2007 ISA crisis. This rapid response and collaboration with authorities helped the industry recover. We also developed the first oral vaccine for SRS, which contributed to reduced antibiotic use. We delivered over 1.6 billion doses of vaccines for salmonids using our technology. • Successful Alliances: We have a proven history of creating successful business partnerships that have exceeded initial projections. Our collaborations with groups like Miqdadi, Ehlinger, SYVA, Biomin (now owned by DSM), and Danisco led to significant market development and growth in various animal health sectors. We sold Centrovet to Virbac in 2021, one of the world’s leading global animal health companies.